AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03121222
Drug: Lactose
RxNorm normalized name: Lactose
DrugBank: Lactose (DB04465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo group received orally two lactose tablets per day. The participants were instructed to receive the capsules every twelve hours. Each individual received the capsules pre-packed in daily doses labeled with the day of consumption. The supplementation period was 30-day for placebo.
Trial: NCT03284294
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo daily for 8 weeks
Trial: NCT01968720
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04547738
Drug: TB treatment according to national guidelines
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: National clinics in Cameroon will initiate TB treatment according to national guidelines upon positive TB diagnosis
Trial: NCT01785433
Drug: Spiriva® Respimat® 5 mcg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01002534
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal instillation of placebo matching in appearance with the Vardenafil instillation
Trial: NCT01856595
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets will be administered QD in each of the cohorts for 14 days (Part A cohorts 1- 5 and Part B cohort 1) or 28 days (Part B cohort 2).
Trial: NCT04346628
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match favipiravir administered orally through day 10.
Trial: NCT02902016
Drug: GED
RxNorm normalized name: Fungederm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four duodenal biopsies will be collected. Two biopsies will stimulated with GED (PPARgamma modulator) ex vivo during 6 hours. Two biopsies will be unstimulated (control).
Trial: NCT04527562
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in this group will be given a starting dose of 2 tablets of Placebo, single or 12 hourly divided dose. After that, they will take one placebo tablet daily for 13 days.Placebo tablet will be identical with the Colchicine tablet. If patients develop gastro intestinal side effects e.g abdominal pain, burning, vomiting, diarrhea, omeprazole and antiemetic will be prescribed. Supportive care and treatment will also be given.
Trial: NCT00002789
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002789
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02106897
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See Arm Descriptions
Trial: NCT03165721
Drug: SGI-110 (guadecitabine)
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: SGI-110 will be administered subcutaneously at 45mg/m\^2/day x 5 days on a 28-day cycle. Cycles may be repeated until there is evidence of tumor progression clinically or by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or there is intolerable toxicity that is not alleviated by dose reduction.
Trial: NCT02143362
Drug: Anesthesia maintenance , propofol,remifentanil,cisatracurium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Closed-loop target controlled infusion of propofol ,Bispectral electroencephalogram index feedback value will be set at 50.~2. Target Controlled Infusion remifentanil , targeted plasma concentrations are 3\~6ng/ml ,maintain heart rate to 60\~100 beats per minute and mean blood pressure to 70\~105 mmHg.~3. Intermittent injection cisatracurium (0.05mg/kg).
Trial: NCT00861484
Drug: GSK958108
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coated Tablets 1 mg
Trial: NCT00861484
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coated tablets
Trial: NCT04867135
Drug: Amikacin Sulfate Injection
RxNorm normalized name: Amikacin Sulfate Injection
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The dose and frequency of amikacin was defined by each hospital.
Trial: NCT02273440
Drug: Theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02273440
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01260246
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo match for 6 months
Trial: NCT04240821
Drug: Theophylline ER
RxNorm normalized name: Theophylline ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral theophylline
Trial: NCT00506077
Drug: Comparator: Placebo (unspecified)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK0249 10mg (2 x 5 mg) Pbo tablet qd for a 28 day treatment period.
Trial: NCT02902172
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood pressure will be monitored during postpartum stay (typical 2 days) and then again at 1 week and 6 weeks (standard practice of care) with blood pressure measurements
Trial: NCT00525798
Drug: SMC021 Oral calcitonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8mg SMC021 - oral calcitonin, once daily
Trial: NCT00525798
Drug: SMC021 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMC021 - Placebo, once daily
Trial: NCT03062904
Drug: Inhaled Bronchodilators +/- Inhaled Methacholine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Combined Salbutamol 200μg and Ipratropium bromure 80μg (2 inhalations) if paradoxal answer~2. Inhaled Methacholine based on international recommendations
Trial: NCT00228254
Drug: Zinc (12.5 mg/day)
RxNorm normalized name: zinc oxide 0.12 MG/MG
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00455260
Drug: hGH-ViaDerm™ System (hGH or somatropin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: transdermal patch; Group 1: 0.2 mg/day SC hGH during Period I, and 0.5 mg per transdermal patch during Period III (expected equivalent dose to SC 0.2 mg/day) Group 2: 0.4 mg/day SC hGH during Period I, and 2.0 mg per transdermal patch during Period III (expected equivalent dose to SC 0.4 mg/day) Group 3: 1.0 mg/day SC hGH during Period I, and 5.0 mg per transdermal patch during Period III (expected equivalent dose to 1.0 mg/day)
Trial: NCT02631135
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In case of tachycardia or hypertension the opioid dose was reduced, in case of bradycardia or hypertension the opioid dose was increased
Trial: NCT00375115
Drug: Sambucol
RxNorm normalized name: Sambucol
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00700687
Drug: PA32540
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aspirin/omeprazole
Trial: NCT00700687
Drug: PA32540 and celecoxib
RxNorm normalized name: amlodipine and celecoxib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aspirin/omeprazole and celecoxib
Trial: NCT01753076
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (0.9% sodium chloride) infusion
Trial: NCT00700687
Drug: aspirin and [NSAID]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aspirin and \[NSAID\]
Trial: NCT02389816
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets
Trial: NCT02131948
Drug: Intranasal placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal spray
Trial: NCT00995345
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT02336594
Drug: RDEA3170 10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02336594
Drug: RDEA3170 2.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00679679
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet counseling and exercise
Trial: NCT02651194
Drug: ABT-493/ABT-530
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet; ABT-493 coformulated with ABT-530
Trial: NCT03179592
Drug: Ultravist 370Mg I/Ml Solution for Injection
RxNorm normalized name: Ultravist 370mg I/ml Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced contrast-volume injection protocols based on patient specific tube voltage.
Trial: NCT00652431
Drug: Vytorin + Niaspan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vytorin (1 tablet containing ezetimibe 10 mg and simvastatin 20 mg) once daily in the morning for 7 days + Niaspan 1000 mg (1 x 1000-mg tablet) once daily in the morning on Days 1 and 2, followed by Niaspan 2000 mg (2 x 1000-mg tablets) once daily in the morning on Days 3 to 7
Trial: NCT00300469
Drug: ABT-335
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 135 mg, daily, 12 weeks
Trial: NCT00300469
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily, 12 weeks, see Arm Description for placebo information
Trial: NCT00368017
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 pill once a day for 12 weeks
Trial: NCT01201798
Drug: Prednisolone acetate 1.0% ophthalmic suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop in study eye, 8 times a day, for 14 days, followed by a 14-day tapering period dependent on the Investigator's determination of adequate response to treatment
Trial: NCT02207699
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 placebo perles given by mouth once
Trial: NCT03633227
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCA matching placebo will be administered per the schedule specified in the arm description.
Trial: NCT02426411
Drug: EMA401 200 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02426411
Drug: EMA401 600 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02426411
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01308320
Drug: fentanyl citrate
RxNorm normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: According to the enrolled group, certain dose of fentanyl is intravenously administered by bolus just after sevoflurane discontinuation.
Trial: NCT02249234
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02432287
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: there is no other name we used for the placebo
Trial: NCT00340678
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with placebo corresponding to each dose of losartan.
Trial: NCT00610935
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intramuscular injection
Trial: NCT01245426
Drug: GW870086 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral inhalation
Trial: NCT01245426
Drug: GW870086 1mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral inhalation
Trial: NCT01245426
Drug: GW870086 3mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral inhalation
Trial: NCT00533637
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citrate buffer with preservatives
Trial: NCT01599754
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice daily
Trial: NCT01476176
Drug: Experimental paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: experimental paracetamol with caffeine
Trial: NCT01476176
Drug: Paracetamol marketed formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: marketed formulation containing caffeine
Trial: NCT02766283
Drug: iodinated contrast agents
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravascular application
Trial: NCT02862561
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin：60mg/m2，5-FU：500mg/m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
Trial: NCT01721408
Drug: Tigecycline
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: every 12 hours (an initial intravenous dose of 100 mg followed by 50 mg twice a day approximately every 12 hours) and placebo intravenous doses every 12 hours beginning 6 hours after the initial intravenous dose of tigecycline for at least for 5 days and up to 14 days.
Trial: NCT00683345
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline 0.67 ml daily subcutaneously as placebo drug.
Trial: NCT01137331
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid- applied once daily prior to bed
Trial: NCT03977727
Drug: Novolog®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novolog® used in a 670G hybrid closed loop continuous subcutaneous insulin infusion system
Trial: NCT00174993
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone placebo-matching tablets, orally, once daily for up to 48 months
Trial: NCT02231255
Drug: Sifrol®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00488618
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-matched placebo oral administration, once per day.
Trial: NCT01595737
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group patients will receive a perfusion of 5% glucose solution. This clear solution, free of visible particles, will have 0.4mg of riboflavin sodium phosphate, 100mg of anhydrous alcohol and water for injection up to 1ml added to it. This solution will be calculated as a dose of 0.1µg/kg/min.
Trial: NCT02781467
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01655823
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment acting as control arm
Trial: NCT00303108
Drug: Pegylated liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/m2 IV on Day 1 of each 28 day cycle
Trial: NCT03806985
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: microcrystalline cellulose capsule
Trial: NCT02252211
Drug: DS-8895a 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received infusions with \^89Zr-Df-DS-8895a at a dose of 0.2 mg/kg on Day 1, DS-8895a at a dose of 1 mg/kg on Days 8 and 22, and \^89Zr-Df-DS-8895a at a dose of 1 mg/kg on Day 36. Patients who responded or had stable disease per RECIST version 1.1 at the Day 50 restaging may have continued to receive biweekly treatment with DS-8895a until disease progression.
Trial: NCT02252211
Drug: DS-8895a 3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received infusions with \^89Zr-Df-DS-8895a at a dose of 0.2 mg/kg on Day 1, DS-8895a at a dose of 3 mg/kg on Days 8 and 22, and \^89Zr-Df-DS-8895a at a dose of 3 mg/kg on Day 36. Patients who responded or had stable disease per RECIST version 1.1 at the Day 50 restaging may have continued to receive biweekly treatment with DS-8895a until disease progression.
Trial: NCT02252211
Drug: DS-8895a 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were to receive infusions with \^89Zr-Df-DS-8895a at a dose of 0.2 mg/kg on Day 1, DS-8895a at a dose of 10 mg/kg on Days 8 and 22, and \^89Zr-Df-DS-8895a at a dose of 10 mg/kg on Day 36. Patients who responded or had stable disease per RECIST version 1.1 at the Day 50 restaging may have continued to receive biweekly treatment with DS-8895a until disease progression.
Trial: NCT05487508
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (NaCl 0.9%)
Trial: NCT01590277
Drug: Active Ethanol
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Target BrAC of 0.1% reached over 30 minutes and then clamped to maintain this dose for an additional 60 minutes. This dose is equivalent to consuming approximately 5 drinks. Administered over a total of 90 minutes.
Trial: NCT01002859
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Injection of NaCl solution
Trial: NCT01590277
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control: no alcohol, administered for a total of 90 minutes.
Trial: NCT01590277
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control: no iomazenil, administered for a total of 10 minutes
Trial: NCT02556021
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, tablet, once daily, oral administration for up to 4 weeks
Trial: NCT03165045
Drug: Spiolto® Respimat®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 weeks
Trial: NCT05274945
Drug: consolidation chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 cycles of FOLFOX or CAPOX
Trial: NCT06369675
Drug: MOB015B vehicle
RxNorm normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical formulation
Trial: NCT01829802
Drug: TDF/FTC (or 3TC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose combination of Tenofovir 300 mg/Emtricitabine 200 mg or Tenofovir 300 mg/Lamivudine 300 mg plus Ritonavir Boosted Atazanavir 300/100mg given once a day
Trial: NCT00218855
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg x 2 mg tablets escalating to 200 mg x 2 until plateau phase. Maintenance 100 mg x 2 until relapse. This procedure is repeated by first relapse.
Trial: NCT01350960
Drug: SPC5001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 weekly SC injections
Trial: NCT01350960
Drug: Saline 0.9%
RxNorm normalized name: CVS Saline 0.9% Nasal Mist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 weekly SC injections
Trial: NCT04470492
Drug: Medical Management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be treated with conventional medication for 3 months.
Trial: NCT02523664
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: effects of hydrocortisone on memory while fMRI
Trial: NCT02523664
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02822339
Drug: BAY987517
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z12-030)
Trial: NCT02023164
Drug: JDP-205 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine, 10mg/mL; a single 1.0 mL injection via intravenous (IV) push over a period of \~2 minutes
Trial: NCT02665234
Drug: Placebo Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle Ophthalmic Solution
Trial: NCT03017248
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% normal saline
Trial: NCT02145923
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy will be performed according to protocols ICE and BEAM (standard scheme)
Trial: NCT01725152
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral suspension, given in 3 divided doses
Trial: NCT01795898
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl transdermal patches releasing 12.5 microgram of fentanyl will be applied for 3 days. The patches will be replaced every 3 days (Day 3, 7 and 10).
Trial: NCT04386616
Drug: MSTT1041A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received one intravenous (IV) infusion of MSTT1041A 700 milligrams (mg) on Day 1. A second IV dose of MSTT1041A 350 mg was given on Day 15 if the participant remained hospitalized with a requirement for supplemental oxygen.
Trial: NCT04386616
Drug: MSTT1041A-matched Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received up to 2 intravenous infusions of MSTT1041A-matched placebo.
Trial: NCT04386616
Drug: UTTR1147A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received one intravenous (IV) infusion of UTTR1147A 90 micrograms/kilogram body weight (μg/kg) on Day 1. A second IV dose of UTTR1147A 90 μg/kg was given on Day 15 if the participant remained hospitalized with a requirement for supplemental oxygen.
Trial: NCT03301766
Drug: standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs prescribed at the discretion of the treating physician (acetaminophen, NSAIDs, muscle relaxants, etc)
Trial: NCT03301766
Drug: Non-medicated patch
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: non-medicated patch
Trial: NCT01037504
Drug: AZD5423
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension for nebulisation, inhaled. Each subject will receive an inhaled dose of AZD5423 or placebo once daily for 14 days. Starting dose as determined from SAD study and with up to 4 dose escalations not exceeding AstraZeneca pre-defined exposure limits.
Trial: NCT01037504
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for nebulisation, inhaled. Each subject will receive an inhaled dose of AZD5423 or placebo once daily for 14 days.
Trial: NCT04386616
Drug: UTTR1147A-matched Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received up to 2 intravenous infusions of UTTR1147A-matched placebo.